Related Experiment Video
Updated: May 2, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Atrial fibrillation in essential hypertension: an issue of concern
1Shanghai Jiao Tong University affiliated first people's Hospital, Shanghai, China.
Insights
Essential hypertension contributes to atrial fibrillation through progressive atrial remodeling. Understanding these changes offers therapeutic windows, potentially through non-antiarrhythmic drugs, to prevent and manage this common arrhythmia.
Area of Science:
- Cardiology
- Clinical Electrophysiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is strongly linked to hypertension, affecting both blood pressure (BP) levels and circadian BP rhythms.
- The precise mechanisms linking essential hypertension to AF, particularly atrial remodeling, require further elucidation.
- Hypertension-induced atrial changes are progressive, creating potential windows for intervention before irreversible remodeling occurs.
Purpose of the Study:
- To review the multifaceted relationship between essential hypertension and atrial fibrillation.
- To explore the underlying mechanisms of AF in hypertensive patients, focusing on atrial remodeling.
- To identify potential therapeutic strategies beyond traditional antiarrhythmic drugs.
Main Methods:
- Review of clinical studies and existing literature on hypertension and atrial fibrillation.
- Analysis of the pathophysiological processes involved in hypertension-induced atrial remodeling.
- Evaluation of current and emerging therapeutic approaches, including non-antiarrhythmic drugs.
Main Results:
- Hypertension promotes AF through mechanisms like myocyte repolarization changes and progressive atrial remodeling (structural and electrical).
- These remodeling processes occur over time, indicating critical periods for intervention.
- While angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) show promise, their benefit in AF is currently limited to hypertensive patients with specific cardiac conditions.
Conclusions:
- Effective prevention and management of AF in essential hypertension necessitate a deeper understanding of progressive atrial remodeling.
- Exploring non-antiarrhythmic drugs targeting atrial remodeling represents a promising new therapeutic avenue.
- Targeted therapies, potentially including ACEIs and ARBs in specific patient subgroups, are crucial for managing AF in the context of hypertension.
Abstract:
Many clinical studies indicate that atrial fibrillation is closely related to hypertension. Atrial fibrillation is not only associated with the level of blood pressure (BP) but also with the circadian rhythms of BP. However, the underlying mechanisms of atrial fibrillation in essential hypertension patients remain largely unknown. Hypertension may facilitate the onset and persistence of atrial fibrillation by stretch-induced changes in the repolarization of atrial myocytes (triggers of atrial fibrillation) and atrial remodeling (structural and electrical remodeling). Importantly, the effects of hypertension on atrial fibrillation are progressive. These progressive anatomic, functional, electrophysiological and structural changes occur at different times. This characterization of the time course of atrial changes presents an intervention window before remodeling progresses to changes that are difficult to reverse. Given that the medium to long-term efficacy of antiarrhythmic drugs has proved poor, it is essential to seek new therapies to prevent the onset of atrial fibrillation and to effectively control recurrences of atrial fibrillation. The study of nonantiarrhythmic drugs that act on the atrial remodeling that constitutes the substrate of the arrhythmia is a new and very interesting field of research. Treatment with angiotensin-converting enzyme inhibitors angiotension-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) seems more promising. However, from recent trials, only hypertension with structural heart disease, left ventricular dysfunction and left ventricular hypertrophy benefit from ACEIs and ARBs. This article reviews many aspects of atrial fibrillatio in essential hypertension patients to provide the foundation of atrial fibrillatio treatment.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Hypertension I: Introduction
Heart Failure II: Pathophysiology
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...

